

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Alzheimer's disease (AD)	Cystatin C (CYSC; CST3)	<p>Studies in mice suggest that inhibiting CYSC could be useful for treating AD. CYSC is an inhibitor of cathepsin B, a <math>\beta</math>-amyloid (A<math>\beta</math>)-degrading protease. In mice, genetic knockout of <i>Cysc</i> lowered levels of soluble and total A<math>\beta</math> plaque load. <i>Cysc</i> deficiency also attenuated A<math>\beta</math>-associated cognitive defects and behavioral abnormalities. Researchers did not disclose their next steps and said they are in discussions with potential partners.</p> <p><b>SciBX 1(40); doi:10.1038/scibx.2008.977</b>  <b>Published online Nov. 6, 2008</b></p>	Patent cooperation treaty patent application filed; available for worldwide licensing	<p>Sun, B. <i>et al. Neuron</i>; published online Oct. 22, 2008;            doi:10.1016/j.neuron.2008.10.001  <b>Contact:</b> Li Gan, University of California, San Francisco, Calif.            e-mail:  <a href="mailto:lgan@gladstone.ucsf.edu">lgan@gladstone.ucsf.edu</a></p>